Associated tags: Food, ALLY, Cataract, Astigmatism, Surgeon, Health, Medical Devices, Optical, Surgery, International, Telephone, Software, ID, Domestic, Webcast, Patient, FDA
Locations: EUROPE, EUROPEAN UNION, FLORIDA, UNITED STATES, NORTH AMERICA
Medical Devices,
Health,
Surgery,
Health Technology,
Other Health,
Optical,
Total,
Surgeon,
Patient,
ALLY,
Growth,
Cataract LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.
- Total revenue for the quarter was $10.6 million, up 28% over the first quarter of 2023.
- Procedure volume in the United States increased approximately 23%, when comparing the first quarter of 2024 to 2023.
- Worldwide procedure volume increased by approximately 25% in the first quarter of 2024 as compared to 2023.
Health,
Medical Devices,
Technology,
Surgery,
Health Technology,
Software,
Optical,
Domestic,
International,
Telephone,
Webcast,
Cataract LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024.
- LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlights.
- To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com .
- Following the live webcast, an archived version of the call will be available on the website.
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock.
- The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company.
- The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.
- The options were granted as of April 1, 2024, as inducements material to each employee entering into employment with the Company.
- The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.
Biotechnology,
Optical,
Surgery,
General Health,
Health,
Medical Devices,
Health Technology,
Other Health,
Cataract,
Depreciation,
Research,
Tax,
Marketing,
Growth,
Adjustment,
Interest,
ALLY,
Cryptocurrency “Our strong performance throughout 2023 continued in the fourth quarter, resulting in total revenue up 18% over the fourth quarter of 2022, with full-year revenue increasing 19%.
Key Points:
- “Our strong performance throughout 2023 continued in the fourth quarter, resulting in total revenue up 18% over the fourth quarter of 2022, with full-year revenue increasing 19%.
- “Half of our 2023 ALLY installations were to new customers, and the vast majority of these ‘new’ LENSAR customers switched from competitive systems.
- The increase from the fourth quarter of 2022 was primarily due to increases in ALLY System sales and procedure volume.
- Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) for the quarter ended December 31, 2023 was ($3.2) million, compared with ($1.8) million for the quarter ended December 31, 2022.
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company’s common stock.
- The options were granted as of March 1, 2024, as inducements material to each employee entering into employment with the Company.
- The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.
Retrieved on:
Monday, February 26, 2024
Software,
Optical,
Surgery,
Health,
Marketing,
Medical Devices,
Communications,
Technology,
International,
Domestic,
Cataract,
ID,
Webcast,
Telephone LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2023 financial results will be released before market open on Monday, March 4, 2024.
- LENSAR’s management will host a conference call and webcast at 8:30 am ET on Monday, March 4, 2024 to discuss the financial results and recent corporate highlights.
- To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com .
- Following the live webcast, an archived version of the call will be available on the website.
Retrieved on:
Thursday, November 9, 2023
Medical Devices,
Health,
Surgery,
Pharmaceutical,
Optical,
Biotechnology,
Adjustment,
Research,
ALLY,
International,
EBITDA,
Telephone,
Interest,
Software,
Tax,
ID,
Depreciation,
Domestic Selling, general and administrative expenses for the quarter ended September 30, 2023 were $5.1 million, a decrease of $1.0 million, or 16%, compared to $6.1 million for the quarter ended September 30, 2022.
Key Points:
- Selling, general and administrative expenses for the quarter ended September 30, 2023 were $5.1 million, a decrease of $1.0 million, or 16%, compared to $6.1 million for the quarter ended September 30, 2022.
- Research and development expenses were $1.5 million and consistent for the quarters ended September 30, 2023, and 2022.
- Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) for the quarter ended September 30, 2023 was $3.2 million, compared with ($3.2) million for the quarter ended September 30, 2022.
- LENSAR management will host a conference call and live webcast to discuss the third quarter results and provide a business update today, November 9, 2023, at 8:30 a.m.
Retrieved on:
Thursday, November 2, 2023
Optical,
Health,
Medical Devices,
Domestic,
Telephone,
ID,
Webcast,
Cataract,
International,
Pharmaceutical industry,
Broadcasting LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023.
Key Points:
- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released before market open on Thursday, November 9, 2023.
- LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, November 9, 2023 to discuss the financial results and recent corporate highlights.
- To access the live webcast, please go to the Investors section of LENSAR’s website at www.lensar.com .
- Following the live webcast, an archived version of the call will be available on the website.
Retrieved on:
Wednesday, August 9, 2023
Surgery,
Medical Devices,
Health,
Optical,
Health Technology,
Tax,
International,
Interest,
Marketing,
Telephone,
Research,
ID,
ALLY,
Domestic,
EBITDA,
Depreciation,
Adjustment,
FDA,
Cataract,
Regulation of tobacco by the U.S. Food and Drug Administration,
Food,
Software,
Cryptocurrency,
Bookkeeping This decrease included approximately $1.0 million of inventory costs charged to research and development in the second quarter of 2022 that did not occur in the same period in 2023.
Key Points:
- This decrease included approximately $1.0 million of inventory costs charged to research and development in the second quarter of 2022 that did not occur in the same period in 2023.
- The second quarter 2023 financial results were significantly impacted by the completion of the May 2023 financing.
- Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”) for the quarter ended June 30, 2023 was ($8.0) million, compared with ($5.9) million for the quarter ended June 30, 2022.
- LENSAR management will host a conference call and live webcast to discuss the second quarter results and provide a business update today, August 9, 2023, at 8:30 a.m.
